Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $670000.0.

  • Legend Biotech's Cash from Financing Activities fell 8421.67% to $670000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $14000.0, marking a year-over-year decrease of 9979.87%. This contributed to the annual value of $5.7 million for FY2024, which is 9928.01% down from last year.
  • Legend Biotech's Cash from Financing Activities amounted to $670000.0 in Q3 2025, which was down 8421.67% from -$990000.0 recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Cash from Financing Activities peaked at $790.0 million during Q2 2023, and registered a low of -$990000.0 during Q2 2025.
  • Its 5-year average for Cash from Financing Activities is $94.9 million, with a median of $925000.0 in 2023.
  • Examining YoY changes over the last 5 years, Legend Biotech's Cash from Financing Activities showed a top increase of 7820009.91% in 2023 and a maximum decrease of 187600.0% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's Cash from Financing Activities stood at $323.6 million in 2021, then crashed by 100.24% to -$783000.0 in 2022, then surged by 218.14% to $925000.0 in 2023, then plummeted by 136.0% to -$333000.0 in 2024, then skyrocketed by 301.2% to $670000.0 in 2025.
  • Its Cash from Financing Activities was $670000.0 in Q3 2025, compared to -$990000.0 in Q2 2025 and $667000.0 in Q1 2025.